Table 1.
Summary of baseline patient characteristics (n patients = 226; n pharmacokinetic samples = 3,821)
| Continuous | Median (min–max) |
|---|---|
| Age, years | 61 (26–81) |
| Duration of cetuximab therapy, months | 5.8 (0.25–27.3) |
| Weight, kg | 72 (41–132) |
| Body surface area, m2 | 1.85 (1.37–2.70) |
| Amphiregulin concentration, pg/mL | 226 (8.50–5080) |
| Epidermal growth factor concentration, pg/mL | 12.7 (0.61–633) |
| Interleukin 8 concentration, pg/mL | 42.0 (1.76–5650) |
| Transforming growth factor‐α concentration, pg/mL | 2.52 (0.404–131) |
| Vascular endothelial growth factor concentration, pg/mL | 278 (46.7–1720) |
| Creatinine clearance, mL/min | 95.5 (31.0–218) |
| Categorical | n (%) |
|---|---|
| Female | 82 (36) |
| RAS mutation present | 81 (36) |
| ECOG performance status | |
| 0 | 154 (68) |
| 1 | 69 (31) |
| 2 | 3 (1) |
| RECIST response achieved | 63 (28) |
ECOG, Eastern Cooperative Oncology Group; RAS, rat sarcoma proto‐oncogene; RECIST, Response Evaluation Criteria in Solid Tumors.